Please login to the form below

Not currently logged in
Email:
Password:

Sanofi Pasteur begins dengue vaccine study

Sanofi Pasteur, the vaccines division of sanofi-aventis has announced it is to begin a paediatric clinical study to test the efficacy of its tetravalent vaccine for dengue fever

Sanofi Pasteur, the vaccines division of sanofi-aventis has announced it is to begin a paediatric clinical study to test the efficacy of its tetravalent vaccine for dengue fever.

The study will be carried out in Thailand in collaboration with Mahidol University of Thailand, the Ministry of Public Health, and the Paediatric Dengue Vaccine Initiative. The programme follows guidelines from the Initiative for Vaccine Research (IVR) led by the World Health Organisation (WHO).

"Large scale paediatric studies are instrumental for the development of a safe and efficacious dengue vaccine to protect against a disease that primarily affects children," said Dr Pratap Singhasivanon, dean of the faculty of tropical medicine, Mahidol University. "We are happy to contribute to an important milestone with the actual start of an efficacy study in Ratchaburi."

Dengue fever is the most widespread tropical disease after malaria. Carried by mosquitoes, the disease is a threat to almost half of the world's population.

18th February 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics